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The tat gene product (Tat) of human immunodeficiency virus type 1 (HIV-1) is an early regulatory protein which transacti-
vates HIV-1 gene expression by interacting with the trans-activation response element (TAR) present in the HIV-1 long
terminal repeat (LTR). In HIV-1-infected cells Tat can also activate the expression of tumor necrosis factor (TNF). Recent
results indicate that essential for this effect is the interaction of Tat with a TAR-like structure present in the TNFbmessenger
RNA leader region that closely resembles the TAR of the HIV-LTR. Here we show that because of this similarity of
mechanisms, the expression of an RNA species encoding polymeric-TAR sequences and known to inhibit Tat-mediated
HIV-1 gene expression also blocks TNF gene expression in response to Tat, but not TNF promoter activation induced by
human T cell leukemia/lymphotropic virus type I Tax protein. Since TNF is increased in HIV-1-infected individuals and can
activate HIV-1 gene expression or rescue Tat-defective HIV-1 proviruses, activation of TNF by Tat may be part of a complex
pathway in which HIV-1 uses its own expression to increase infectivity and to induce disease. This study shows a dual role
for the polymeric-TAR construct in inhibiting HIV-1 replication and strengthens the potential use of this protective gene in
gene therapy for AIDS. q 1996 Academic Press, Inc.
necrosis factor (TNF) a and b (25–27 ), transformingThe human immunodeficiency virus type 1 (HIV-1) en-
growth factor b (28) and others according to the cell typecodes an early regulatory protein called Tat (1, 2). Tat
(reviewed in Ref. 29). In particular, TNF is increased intransactivates HIV-1 gene expression by interacting with
HIV-1-infected individuals (30, 31) and is known to affectthe Tat-activation response element (TAR) in the HIV long
the vascular, immune, and central nervous systems, sug-terminal repeat (LTR) (3 – 7 ). Tat promotes transcriptional
gesting a role for this cytokine in the pathogenesis ofinitiation of the integrated proviral genome and stimu-
AIDS-KS, B cell lymphomas, and central nervous systemlates the elongation of newly initiated viral transcripts (8–
disorders (14, 25, 32–34 ). In addition, TNF activates HIV-10). Tat has also been shown to be released by infected T
1 gene expression and rescues Tat-defective HIV-1 provi-cells (11–13). In this extracellular form Tat activates HIV
ruses (14, 35, 36). TNF can also increase production ofreplication and rescues Tat-defective proviruses in a par-
interleukin 1 (IL-1) and IL-6 (25), which are increased inacrine fashion (10–12, 14 –18). By a different mechanism
HIV-1-infected individuals (37, 38). Thus, activation of(receptor-mediated) extracellular Tat participates in the
TNF by Tat may be part of a complex pathway in whichdevelopment and progression of Kaposi’s sarcoma (KS)
HIV-1 uses viral products and host factors to increase(11, 12, 14, 19–23). In addition, recent data indicate that
its own expression, infectivity, and to induce disease (25).Tat is involved in the T cell death occurring in AIDS by
Because of these effects of TNF, it is critical that anyinducing or contributing to apoptosis (13, 24 ). In HIV-1-
gene therapy approach be able to block the Tat-inducedinfected or tat-transfected cells or when extracellular Tat
gene expression of TNF in addition to inhibiting HIV repli-is present at high concentrations, Tat can also activate
cation.the expression of several cellular genes including tumor
The TAR element is present in all HIV RNA transcripts
and forms a predicted stem–loop secondary structure
that is required for Tat function (5, 6). Expression of TAR1 Present address: Research Institute for Genetic and Human Ther-
apy, Pavia, Italy and Gaithersburg, MD. RNA (polymeric-TAR) has been found to act as a decoy
2 To whom correspondence and reprint requests should be ad-
to bind and sequester Tat produced in the cells (39–43)dressed at Laboratory of Virology, Istituto Superiore di Sanita´, Viale
or taken up by the cells (44 ), thus preventing its bindingRegina Elena 299, 00161 Rome, Italy. Fax: (396) 44-53-36-9. E-mail:
ensoli@virus1.iss.infn.it. to the TAR sequence encoded by the viral RNA. This
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results in the lack of activation of viral gene expression
and diminished generation of progeny virus.
Recent data indicate that Tat-induced TNFb gene ex-
pression is mediated by a TAR-like element present in
the TNFb 5* untranslated region although both SP1 and
NFkB binding sites are also required for Tat activity (26).
The TNFb messenger RNA leader region, in fact, con-
tains a sequence which is 80% homologous to the bulge
of the TAR and forms a predicted stem–loop structure
that closely resembles the TAR of the HIV-LTR (TAR-like).
This region is essential for TNFb transactivation by Tat
(26). This apparent similarity of mechanisms suggested
that the polymeric-TAR construct may inhibit Tat-medi-
ated TNFb gene expression in addition to inhibition of
HIV-1 gene expression.
To test this hypothesis, cotransfection experiments
were performed with CD4/ T cell lines such as Jurkat
cells, H9 cells permanently transduced with the first exon
of Tat (H9-Tat 1) and the 8E51 cell line which is chroni-
cally infected with a pol-defective HIV-1 provirus (26, 45).
These cell lines were maintained in RPMI-1640 medium
supplemented with 10% fetal bovine serum at 377 in a
humidified atmosphere containing 5% carbon dioxide in
air. The plasmids used for the transfection experiments
included pTNFbCAT and pCD7CAT which contain the
chloramphenicol acetyltransferase (CAT) reporter gene
FIG. 1. Inhibition of Tat-mediated activation of the TNFb promoterlinked to the TNFb-promoter (pTNFbCAT) or HIV-1 LTR
or the HIV-1 LTR by polymeric-TAR in Jurkat cells. Representative CAT
(pCD7CAT) described previously (26, 46). The pCVTAT assays are shown. (A) Cotransfection of pTNFbCAT (2 mg) and pCVTAT
plasmid and its control vector, pCV0, have also been (2 mg) or pCVO (2 mg) with LTR-0 TAR (6 mg) or LTR-50 TAR (6 mg). (B)
described (1, 44 ). The human T cell leukemia/lympho- Cotransfection of pCD7CAT (1 mg) and pCVO (3 mg) with LTR-50 TAR
(3 mg) or LTR-O TAR (3 mg) in the presence or absence of pCVTAT (0.1tropic virus type I (HTLV-I) Tax plasmid (47 ) and the plas-
mg). CAT activity from cells transfected with the pCD7CAT ormids LTR-50 TAR and the control vector LTR-0 TAR con-
pTNFbCAT, PCVTAT, and LTR-O TAR was given a value of 100%. The
tain 50 and 0 copies, respectively, of the TAR element percentage of relative CAT activity is shown at the bottom.
under the control of the HIV-1-LTR promoter (39, 41), have
all been described. Transfection of the plasmid DNA was
performed by the electroporation procedure (25). Briefly, compared to cells transfected with the control vector
LTR-0 TAR, reaching almost the baseline levels observedcells (3 1 107) were resuspended in 0.25 ml of growth
medium containing 1 mM EGTA and mixed gently with in the absence of Tat (Fig. 1A and Table 1A). Since LTR-
50 TAR and LTR-0 TAR induced the same TNFbCAT activ-plasmid DNA. After 10 min incubation on ice, cells were
electroporated at 960 m Far, 0.25 kV. After an additional ity in the absence of pCVTAT, this suggests that LTR-50
TAR alone does not suppress TNFb-CAT transcription.10 min on ice, the cells were resuspended in 30 ml of
growth medium and harvested 72 hr later. CAT assays Therefore, the difference in TNFbCAT activity observed
with the LTR-50 TAR and the LTR-0 TAR in the presencewere performed on cell lysate (normalized to total protein
content) as described previously (46). of pCVTAT is really dependent on the ability of LTR-50
TAR to trap the Tat protein and it is not due to the activa-To test whether the polymeric-TAR construct may in-
hibit Tat-mediated TNFb gene expression, 2 mg of tion of other inhibitory activities such as the effect of
double-stranded kinase which has been reported to bepTNFbCAT and 2 mg of either pCVTAT or pCV0 were
cotransfected with 6 mg of either LTR-0 TAR or LTR-50 activated by TAR (48).
To compare the level of transactivation or inhibitionTAR into Jurkat cells. The amount of polymeric-TAR DNA
transfected in these experiments is about a 2-fold and a of TNFb-mediated gene expression with the HIV-1 LTR-
mediated gene expression by Tat or polymeric-TAR, re-3-fold molar excess of pTNFbCAT and pCVTAT, respec-
tively. As shown in Fig. 1A and Table 1A, pCVTAT in- spectively, pCD7CAT (1 mg), pCV0 (3 mg), and either LTR-
0 TAR or LTR-50 TAR (3 mg) were cotransfected in thecreased pTNFbCAT activity by 4.7-fold, as compared to
the control vector pCV0, and the polymeric-TAR decoys presence or absence of pCVTAT (0.1 mg) into Jurkat cells
(Fig. 1B). pCVTAT activated HIV-1 LTR-CAT (pCD7CAT)inhibited Tat-mediated TNFb gene expression by 4.4-fold
(Table 1A) or 71% (Table 1B) and up to 78% (Fig. 1A) as by 135-fold as compared to the control vector pCV0 and
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TABLE 1A
Activation of TNFb-CAT or HIV-1 LTR-CAT Gene Expression by Tat
and Inhibition by the Poly-TAR Decoy
Percentage
of CAT Activation
Plasmid DNA activity inhibition
pTNFbCAT / pCV0 / LTR-0 TAR 1.7
pTNFbCAT / pCVTAT / LTR-0 TAR 8 4.7X
pTNFbCAT / pCVTAT / LTR-50 TAR 1.8 4.4X
(78%)
pCD7CAT / pCV0 / LTR-0 TAR 0.17
pCD7CAT / pCV0 / pCVTAT / LTR-0 TAR 23 135.3X
pCD7CAT / pCV0 / pCVTAT / LTR-50 TAR 0.83 27.7X
(96%)
Note. Jurkat cells were transfected with pTNFbCAT (2 mg), pCV0 (2 mg),
or pCVTAT (2 mg) and LTR-0 TAR (6 mg) or LTR-50 TAR (6 mg); or with FIG. 2. Inhibition of Tat-mediated activation of the TNFb promoter
pCD7CAT (1 mg), pCV0 (3 mg), and LTR-50 TAR (3 mg) or LTR-0 TAR (3 mg) by polymeric-TAR in HIV-1 chronically infected 8E51 cell line. Shown
in the presence or absence pCVTAT (0.1 mg). CAT activity was determined is a representative CAT assay after transfection of pTNFbCAT (5 mg)
as described previously (18). The percentage of CAT activity is shown. and LTR-50 TAR (50 TAR) (5 mg) or LTR-0 TAR (0 TAR) (5 mg) into 8E51
The numbers in parenthesis refer to the percentage of inhibition of CAT cell line. Ten micrograms of pCD7CAT were transfected into 8E51 cells
activity by poly-TAR decoys compared with that of the control vector LTR- as a positive control. Shown at the bottom is the percentage of relative
0 TAR. X, fold of activation or inhibition by Tat or poly-TAR, respectively. CAT activity.
the polymeric-TAR inhibited Tat-induced HIV-1 LTR-CAT of Tat and in a cell line chronically infected with a pol-
activity by 27.7-fold or 96% inhibition (Fig. 1B and Table defective HIV-1 provirus (25). To determine whether poly-
1A). Thus, polymeric-TAR decoy can inhibit both TNF and meric-TAR could inhibit TNFb activation in these sys-
HIV-1 promoter activation induced by Tat. However, since tems, 5 mg of pTNFbCAT and 5 mg of either LTR-50 TAR
these experiments were done by a transient transfection or its control LTR-0 TAR were transfected into these two
system, only some of the cells will take up at the same cell lines. For 8E51 cells, pCD7CAT was used as a posi-
time all the plasmids. This may reduce the efficacy of tive control to demonstrate the endogenous expression
the polymeric-TAR construct which in permanently ex- of functional Tat protein. As shown in Fig. 2 and Table
pressing cells has been shown to inhibit up to 99% of 1B, polymeric-TAR inhibited Tat-induced TNFb gene ex-
viral replication (41). pressions in both cell lines.
We have previously shown that the TNFb promoter is We have previously shown that polymeric-TAR does
activated in cells constitutively expressing the first exon not affect Tax-induced expression of HTLV-I (39) and that
Tax activates TNFb gene expression by acting through
the Sp1 and NFkB binding sites and does not requireTABLE 1B
the TAR-like structure (26, 49, 50). To test whether inhibi-
Inhibition of Tat-Mediated Activation of the TNFb Promoter by
tion by polymeric-TAR was specific for Tat-mediatedPolymeric-TAR in Human CD4/ T Cell Lines
TNFb gene expression, the Tax expressing plasmid
TNFbCAT activity (%) HTLV-Tax (47 ) was cotransfected with the pTNFbCAT
Percentage of and LTR-50 TAR or the control vector (LTR-0 TAR) into
Cell line LTR-0 TAR LTR-50 TAR Inhibition Jurkat cells. Although Tax did induce TNFb gene expres-
sion, this activation was not inhibited by polymeric-TAR;Jurkat / TAT 100 29 [22–34] 71 [66–78]
in fact, the levels of TNFb gene expression were theH9TAT 1 100 23 [3–45] 77 [55–97]
8E51 100 53 [9–70] 47 [30–91] same in cells transfected with polymeric-TAR or with the
Jurkat / TAX 100 136 [96–171] 0 vector alone (Fig. 3 and Table 1B), indicating that poly-
meric-TAR specifically interferes with Tat function.
Note. pCVTAT (2 mg) or HTLV-TAX (2 mg) and pTNFbCAT (2 mg) were
These results reinforce our earlier work showing thatcotransfected with LTR-50 TAR (6 mg) or LTR-0 TAR (6 mg) into Jurkat
Tat activates TNFb gene expression through a TAR-likecells; or pTNFbCAT (5 mg) and LTR-50 TAR (5 mg) or LTR-0 TAR (5 mg)
were transfected into H9TAT 1 or 8E51 cells. CAT activity was deter- structure in both tat-transfected or HIV-1-infected CD4/
mined as described previously (18). Percentage of relative TNFbCAT T cells and indicate that polymeric-TAR decoys can spe-
activity and percentage of inhibition by LTR-50 TAR was calculated on cifically inhibit Tat-induced TNFb gene expression. Par-
the level of CAT activity obtained with the control vector LTR-0 TAR.
ticularly, the control with the Tax expressing construct isShown are the average values and the number in brackets indicates
to demonstrate the different mechanism of transcrip-the range of minimum and maximum values obtained in three to six
repeated experiments for each cell type. tional activation between Tat and Tax and therefore the
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